A rare CALR variant mutation and a review of CALR in essential thrombocythemia.

Robert Diep, Ara Metjian

Journal: Journal of thrombosis and thrombolysis 2018;45(3):457-462

PMID: 29411299

Abstract

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm characterized by megakaryocyte hyperplasia, thrombocytosis, thrombotic and hemorrhagic complications, and potential transformation into myelofibrosis and acute myeloid leukemia. The vast majority of cases are driven by a somatic mutation in JAK2, CALR, or MPL. CALR, a gene that codes for the calcium-binding chaperone calreticulin, is the predominant mutation in patients with non-mutated JAK2 essential thrombocythemia, accounting for 20-25% of the overall somatic mutation frequency in ET. In this brief review of ET, we introduce a rare CALR mutation through a case presentation of a 58-year-old man with diffuse pulmonary emboli in the setting of thrombocytosis. We subsequently characterize the main types of CALR mutations and their value in diagnosis and prognosis of disease course, and lastly discuss the current clinical approach to ET.

Address: Department of Medicine, Duke University Medical Center, Durham, NC, USA. [email protected].; Duke University Health System, DUMC 3912, Durham, NC, 27710, USA. [email protected].; Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.; Duke University Health System, DUMC 3912, Durham, NC, 27710, USA.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.